Clin Psychopharmacol Neurosci.
2024 Feb;22(1):33-44. 10.9758/cpn.23.1098.
Exploring Clinical Subgroups of Participants with Major Depressive Disorder that may Benefit from Adjunctive Minocycline Treatment
- Anmella G
1,2,3,4,5 - Meehan A6
- Ashton M6
- Mohebbi M6,7
- Fico G1,2,3,4,5
- Ng CH8
- Maes M6,9
- Berk L6
- Prisco MD1,2,3,4,5
- Singh AB6
- Malhi GS10,11,12
- Berk M6,13,14,15
- Dodd S6,13,14
- Hidalgo-Mazzei D1,2,3,4,5
- Grande I1,2,3,4,5
- Pacchiarotti I1,2,3,4,5
- Murru A1,2,3,4,5
- Vieta E1,2,3,4,5
- Dean OM6,15
- Affiliations
-
- 1Department of Psychiatry and Psychology, Institute of Neuroscience, Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain
- 2Bipolar and Depressive Disorders Unit, Digital Innovation Group, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain
- 3Biomedical Research Networking Centre Consortium on Mental Health (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain
- 4Department of Medicine, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain
- 5Institute of Neurosciences (UBNeuro), Barcelona, Spain
- 6Deakin University, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, VIC, Australia
- 7Deakin University, Faculty of Health, Biostatistics Unit, Geelong, VIC, Australia
- 8The Melbourne Clinic, Department of Psychiatry, University of Melbourne, Melbourne, VIC, Australia
- 9Department of Psychiatry, Chulalongkorn University, Bangkok, Thailand
- 10Department of Psychiatry, Northern Clinical School, The University of Sydney, Faculty of Medicine and Health, Sydney, NSW, Australia
- 11Academic Department of Psychiatry, Northern Clinical School, The University of Sydney, Sydney, NSW, Australia
- 12CADE Clinic, Royal North Shore Hospital, Northern Sydney Local Health District, Sydney, NSW, Australia
- 13Orygen, The National Centre of Excellence in Youth Mental Health, Parkville, VIC, Australia
- 14Department of Psychiatry, University of Melbourne, Parkville, VIC, Australia
- 15Florey Institute for Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
- KMID: 2553609
- DOI: http://doi.org/10.9758/cpn.23.1098
Abstract
Objective
To explore illness-related factors in patients with major depressive disorder (MDD) recipients of adjunctive minocycline (200 mg/day) treatment. The analysis included participants experiencing MDD from a 12-week, double blind, placebo-controlled, randomized clinical trial (RCT).
Methods
This is a sub-analysis of a RCT of all 71 participants who took part in the trial. The impact of illness chronicity (illness duration and number of depressive episodes), systemic illness (endocrine, cardiovascular and obesity), adverse effects and minocycline were evaluated as change from baseline to endpoint (12-week) using ANCOVA.
Results
There was a consistent but statistically non-significant trend on all outcomes in favour of the use of adjunctive minocycline for participants without systemic illness, less illness chronicity, and fewer adverse effects.
Conclusion
Understanding the relationship between MDD and illness chronicity, comorbid systemic illness, and adverse effects, can potentially better characterise those individuals who are more likely to respond to adjunctive anti-inflammatory medications.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Protocol and Rationale-The Efficacy of Minocycline as an Adjunctive Treatment for Major Depressive Disorder: A Double Blind, Randomised, Placebo Controlled Trial
- The Effects of Adjuvant Therapy of Atypical Antipsychotics on the Change of Clinical Symptoms in Patients with Major Depressive Disorder in a University Hospital: 1 Year Follow-Up Study
- Comparison of Clinical Characteristics among Anxiety Disorder, Depressive Disorder, and Co-morbid of Anxiety Disorder and Depressive Disorder with MMPI-2-RF
- A Case of Bright Light Therapy in a Treatment Resistant Patient with Major Depressive Disorder
- A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat
